

## RESPONSE TO ABIRATERONE AND ENZALUTAMIDE IN CASTRATE-RESISTANT PROSTATE CANCER IN CLINICAL PRACTICE

Ranz Ortega P , Diez Fernández R , Molina García T.

### PURPOSE

In order to clarify the optimal sequence of treatment of abiraterone and enzalutamide in castrate-resistant prostate cancer (mCRPC) we determine the **response** in prostate-specific antigen (**PSA**) levels in mCRPC patients treated with **abiraterone or enzalutamide**.

### MATERIALS and METHODS

Single-center, retrospective, observation study  
mCRPC treated with abiraterone or enzalutamide  
January 2012 – August 2017

- ✓ Dose
- ✓ Treatment duration
- ✓ Starting date

*From electronic prescription program*

- ✓ Age
- ✓ Tumor extensión
- ✓ Metastasis
- ✓ Diagnosis date
- ✓ Previous treatments:

*complete androgen deprivation therapy, radiotherapy, docetaxel and prostatectomy*

- ✓ PSA testing:  
at the beginning, 4, 8 and 24 weeks
- ✓ Proportion of patients who achieved 50% and 90% PSA reduction

*From patient clinical analysis*

*From patient clinical records*

Descriptive statistics were performed with SPSS 20.00

### RESULTS

N=67

Age: 78±7 years  
Mean Gleason grade:8  
Main metastatic location:  
bone and regional lymph node

Previous treatment	Abiraterone	Enzalutamide
Prostatectomy		62%
Androgen deprivation therapy	51%	87%
Radiotherapy	73%	50%
Pretreated with abiraterone	x	15%
Mean time from diagnosis to drug (y)	6,7	4,3

Abiraterone	4 weeks (%)		8 weeks (%)		24 weeks (%)	
	PSA 50%	PSA 90%	PSA 50%	PSA 90%	PSA 50%	PSA 90%
1st line (n=35)	45	24	66	67	64	64
2nd line (Post-DTX)* (n=11)	18	0	36	0	27	9
Enzalutamida	4 weeks (%)		8 weeks (%)		24 weeks (%)	
	PSA 50%	PSA 90%	PSA 50%	PSA 90%	PSA 50%	PSA 90%
1st line (n=7)	43	14	40	20	75	25
2nd line (n=10)	11	0	22	22	44	44
3rd line (Post-DTX)*(n=4)	25	0	25	0	75	50

### CONCLUSIONS

- ✓ Treatment with **abiraterone** needs to be continued **at least for 8 week** in order to obtain **significant PSA reductions** in most patients.
- ✓ **Abiraterone refractory** patients still achieve significant **PSA reductions with enzalutamide** although require longer periods of treatment to do so.